Timothy J Guzi

USPTO Granted Patents = 64 (Patent Applications = 5)

CIPO Patents = 5

EPO Patents = 24 (Patent Applications = 9)

Average Co-Inventor Count = 5.2

ph-index = 13

Forward Citations = 438(Granted Patents)

Inventors with similar research interests:

Location History:

Chatham, NJ (US) (2000 - 2014)
Sudbury, MA (US) (2009 - 2019)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

6 out of 52

Pharmacopeia Drug Discovery, Inc.

Blueprint Medicines Corporation

where one patent can have more than one assignee

Years Active: 2000-2019

Loading Chart...

64 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10227329 - Compounds useful for treating disorders related to RET (2019-03-12),

2. 9730940 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2017-08-15),

3. 9206142 - Anilinopiperazine derivatives and methods of use thereof (2015-12-08),

4. 9062071 - Substituted piperidines as HDM2 inhibitors (2015-06-23),

5. 8993535 - Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors (2015-03-31),

6. 8859776 - Substituted piperidines that increase p53 activity and the uses thereof (2014-10-14),

7. 8673924 - Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors (2014-03-18),

8. 8603998 - Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors (2013-12-10),

9. 8586576 - Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors (2013-11-19),

10. 8580782 - Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors (2013-11-12),

11. 8476278 - Thiazole Derivatives as protein kinase inhibitors (2013-07-02),

12. 8318735 - 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors (2012-11-27),

13. 8293747 - Heterocyclic amide compounds as protein kinase inhibitors (2012-10-23),

14. 8211854 - Methods for inhibiting protein kinases (2012-07-03),

15. 7807683 - N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors (2010-10-05),

Title: Timothy J Guzi: Innovator Extraordinaire in Pharmaceutical Research

Introduction:

Timothy J Guzi is a prominent inventor and innovator within the field of pharmaceutical research. With a stellar career spanning several renowned companies, including Schering Corporation and Merck Sharp & Dohme Corporation, Guzi has earned an outstanding reputation for his contributions to scientific advancements. Born in Chatham, NJ, Guzi has remained dedicated to pushing the boundaries of medical technology, as evidenced by his impressive portfolio of 64 patents.

Latest Patents:

Guzi's recent patents showcase his expertise in developing compounds and pharmaceutical compositions that address complex disorders and diseases. Two notable patents exemplify his innovative approach:

1. Compounds useful for treating disorders related to RET:

Described within this patent are compounds designed to inhibit wild-type RET and its resistant mutants. These compounds hold great promise in treating various disorders linked to RET, offering hope to patients seeking effective therapies.

2. Purine inhibitors of human phosphatidylinositol 3-kinase delta:

This groundbreaking patent presents compounds that act as inhibitors of PI3K-delta. By targeting this essential enzyme, these compounds exhibit potential in treating diseases such as inflammation, asthma, COPD, and cancer, all of which are influenced by PI3K-delta-mediated pathways.

Career Highlights:

Throughout his career, Guzi has consistently demonstrated his dedication to advancing pharmaceutical research. From his early days at Schering Corporation to his significant contributions at Merck Sharp & Dohme Corporation, Guzi's impact is undeniable. His collaborative nature and exceptional problem-solving skills have enabled the development of new and improved treatments for various diseases.

Collaborations:

Guzi has worked alongside esteemed colleagues such as Kamil Paruch and Michael P Dwyer. These collaborations have resulted in further innovations in the pharmaceutical field and underscore Guzi's commitment to teamwork and knowledge-sharing. The exchange of ideas within these partnerships has undoubtedly contributed to Guzi's remarkable success.

Conclusion:

Timothy J Guzi's exceptional patent record, coupled with his impressive career trajectory, places him among the leading innovators in pharmaceutical research. His contributions have the potential to transform the lives of countless individuals grappling with complex disorders and diseases. Guzi's ingenuity and collaborative spirit have undoubtedly left an indelible mark on the field, further cementing his legacy as an influential figure in the world of inventions and patents.

This text is generated by artificial intelligence and may not be accurate.